PER 0.00% 7.5¢ percheron therapeutics limited

Ann: Positive PDCO opinion and A$20m Placement, page-61

  1. 4,683 Posts.
    lightbulb Created with Sketch. 1086
    In the Biotech realm - we are on the home stretch....seriously.

    A 'pivotal' trial with 'Futility' results mid 2023.

    Hint to future activities is the appointment of Prof Voit as PI for Phase 2II/3.

    I will be very surprised if we are here talking about commercialization....

    Lets see how we go.
    .
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.